Corning Incorporated (NYSE: GLW) announces its new Corning® TransportoCells™ designed to help accelerate a key step in the drug discovery and development process.
Corning TransportoCells allow researchers to more efficiently screen potential drug candidates for drug-transporter inhibition and drug-transporter-reaction phenotyping, two important parameters related to drug-drug interactions.
Corning TransportoCells are high-performance mammalian cells in a convenient, cryopreserved format that transiently overexpress individual human solute carrier (SLC) transporter proteins. The latest innovation was unveiled at the 10th Annual Meeting of the International Society for the Study of Xenobiotics (ISSX), Sept. 29 - Oct. 3 in Toronto.
“Culturing and maintaining transporter cell lines can be expensive and time-consuming, taking a week or more to prepare cells for assaying,” said Dr. Charles Crespi, Discovery Labware business director, Corning Life Sciences. “Corning TransportoCells can be thawed, plated and assayed in just two days with high-uptake ratios, delivering robust data while eliminating the time required to culture and maintain stable cell lines.”
The Corning TransportoCells were developed by leveraging Gentest™ technology obtained as part of Corning’s acquisition of Becton Dickinson’s Discovery Labware business in 2012. Corning TransportoCells complement Corning’s full range of cell culture and bioprocess solutions, including innovative vessels for research through scale-up; advanced cell culture surfaces to grow attachment-dependent and unattached cells; and a range of Corning cellgro® media, sera, and custom solutions for cell culture applications.
Corning TransportoCells features include:
• A cryopreserved format that provides flexibility for experimental planning
• Cells that are readily available, can be stored onsite, and shipped globally
• Cells that can be thawed, plated, and assayed in just two days
• Robust results with equal, or greater than, 10-fold uptake ratios
• Consistency with other mammalian cell-based models
• Individual vials that contain 10 million cells and support one 24-well or one 96-well assay plate
• All current USFDA and European Medicines Agency (EMA)-recommended SLC drug transporters
For companies looking to outsource their SLC Transporter Interaction Studies using Corning TransportoCells, Corning GentestSM Contract Research Services will also be available beginning in 2014. All assays are designed to meet regulatory agency recommendations.
Through acquisition and ongoing research and development investment, Corning now offers a more comprehensive range of premium and innovative laboratory products and solutions for a wide spectrum of life science applications. Corning’s trusted quality brands – backed by technical expertise – provide researchers with better ways to advance their research from the beginning of their process to the end. The family of brands includes Corning®, Falcon®, Corning cellgro®, PYREX®, Axygen®, and Gosselin™.
Corning TransportoCells are available to customers worldwide. To learn more about the new Corning TransportoCells or any Corning Life Sciences products, please contact a customer service representative at 1-800-492-1110 toll free in the United States; (+1) 1-978-442-2200 internationally; or visit www.corning.com/lifesciences .
Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effect of global political, economic and business conditions; conditions in the financial and credit markets; currency fluctuations; tax rates; product demand and industry capacity; competition; reliance on a concentrated customer base; manufacturing efficiencies; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.
About Corning Incorporated
Corning Incorporated ( www.corning.com ) is the world leader in specialty glass and ceramics. Drawing on more than 160 years of materials science and process engineering knowledge, Corning creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications and life sciences. Our products include glass substrates for LCD televisions, computer monitors and laptops; ceramic substrates and filters for mobile emission control systems; optical fiber, cable, hardware & equipment for telecommunications networks; optical biosensors for drug discovery; and other advanced optics and specialty glass solutions for a number of industries including semiconductor, aerospace, defense, astronomy, and metrology.